logo-loader
viewArix Bioscience PLC

Arix Bioscience notes portfolio company Iterum releases topline results for a Phase 3 trial of novel antibiotic, sulopenenem

Iterum said the full body of evidence from the trial, known as Sulopenem for Resistant Enterobacteriaceae (SURE) 3, confirms overall safety profile

Drugs

Arix Bioscience PLC (LON:ARIX), a global venture capital company focused on investing in and building breakthrough biotech companies, today noted that its portfolio company, Iterum Therapeutics Plc (NASDAQ:ITRM) announced topline results from one of its three Phase 3 trials for sulopenem, Iterum’s lead compound and novel antibiotic for the treatment of gram-negative, multi-drug resistant infections.

In a statement, Arix pointed out that Iterum said the full body of evidence from the trial, known as Sulopenem for Resistant Enterobacteriaceae (SURE) 3, confirms overall safety profile and suggests that treatment with sulopenem may result in clinically important benefits in complicated intra-abdominal infections, the second leading cause of infection-related mortality in intensive care units.

However, it added, the trial narrowly missed its primary endpoint of clinical response on Day 28 in the micro-MITT[1] population, by one patient.

As reported by Iterum, results from its SURE 1 and SURE 2 Phase 3 trials for complicated and uncomplicated urinary tract trials are expected to read out in the first quarter of 2020.

The full announcement can be accessed on Iterum’s investor website: https://ir.iterumtx.com/press-releases

Quick facts: Arix Bioscience PLC

Price: 96 GBX

LSE:ARIX
Market: LSE
Market Cap: £130.13 m
Follow

NO INVESTMENT ADVICE

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

In exchange for publishing services rendered by the Company on behalf of Arix Bioscience PLC named herein, including the promotion by the Company of Arix Bioscience PLC in any Content on the Site, the Company...

FOR OUR FULL DISCLAIMER CLICK HERE

Watch

Artios in strong position to accelerate cancer programmes after Arix investment

Proactive Investors' Andrew Scott sits down with Arix Bioscience Plc's (LON:ARIX) investment director Jonathan Tobin and Niall Martin, chief executive of Artios Pharma. Arix has recently upped its stake in Artios following a Series B financing round that was backed by the venture capital...

on 21/8/18

2 min read